The role of b-blockers in the new revision of the 2018 European guidelines for the diagnosis and treatment of arterial hypertension in the patients with comorbidities

Abstract

The review from the standpoint of the newest European guidelines for the diagnosis and treatment of arterial hypertension discusses the role of highly selective b-blockers and, above all, the superior member of these drugs - bisoprolol in blood pressure lowering therapy in comorbid patients with arterial hypertension. In terms of evidence-based medicine, the benefits of bisoprolol in patients with comorbid coronary heart disease, chronic heart failure, atrial fibrillation, and aortic pathology are discussed. The data on the feasibility and the possibility of including in the therapy highly selective b-adrenergic blockers in patients with chronic obstructive pulmonary disease, peripheral artery disease, diabetes and sexual dysfunction are presented

Keywords

• arterial hypertension
• recommendations
• bisoprolol
• comorbid diseases
• cardiovascular risk
• prognosis